Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer
PurposeThis study aimed to evaluate the rates of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 heterogeneity in multifocal or multicentric breast cancer (MMBC) and its association with treatment pattern and disease outcomes.MethodsMMBC...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.833093/full |
| _version_ | 1811241473079771136 |
|---|---|
| author | Shuai Li Jiayi Wu Ou Huang Jianrong He Weiguo Chen Yafen Li Xiaosong Chen Kunwei Shen |
| author_facet | Shuai Li Jiayi Wu Ou Huang Jianrong He Weiguo Chen Yafen Li Xiaosong Chen Kunwei Shen |
| author_sort | Shuai Li |
| collection | DOAJ |
| description | PurposeThis study aimed to evaluate the rates of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 heterogeneity in multifocal or multicentric breast cancer (MMBC) and its association with treatment pattern and disease outcomes.MethodsMMBC patients with ER, PR, HER2, and Ki67 results for each tumor focus were retrospectively analyzed using Kappa test and categorized into the homogeneous group (Homo group) and the heterogeneous group (Hetero group). Chi-square tests were performed to compare the clinical features and treatment options between the groups. Disease-free survival (DFS) and overall survival (OS) rates were estimated from Kaplan–Meier curves and compared between two groups.ResultsA total of 387 patients were included, and 93 (24.0%) were classified into the Hetero group. Adjuvant endocrine therapy was more frequently assigned for patients in the Hetero group than in the Homo group (84.9% vs. 71.7%, p = 0.046). There was no difference in terms of adjuvant anti-HER2 therapy (28.3% vs. 19.6%, p = 0.196) and chemotherapy (69.9% vs. 69.8%, p = 0.987) usage between the two groups. At a median follow-up of 36 months, DFS rates were 81.2% for the Hetero group and 96.5% for the Homo group (p = 0.041; adjusted HR, 2.95; 95% CI, 1.04–8.37). The estimated 3-year OS rates for the groups were 95.8% and 99.5%, respectively (p = 0.059; adjusted HR, 5.36; 95% CI, 0.97–29.69).ConclusionHeterogeneity of ER, PR, HER2, or Ki67 was present in 24.0% patients with MMBC. Biomarkers heterogeneity influenced adjuvant endocrine therapy usage and was associated with worse disease outcomes, indicating further clinical evaluation. |
| first_indexed | 2024-04-12T13:36:35Z |
| format | Article |
| id | doaj.art-9614c19decfa4cdfbd4a3d198a684368 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T13:36:35Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-9614c19decfa4cdfbd4a3d198a6843682022-12-22T03:30:59ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-06-011210.3389/fonc.2022.833093833093Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast CancerShuai LiJiayi WuOu HuangJianrong HeWeiguo ChenYafen LiXiaosong ChenKunwei ShenPurposeThis study aimed to evaluate the rates of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 heterogeneity in multifocal or multicentric breast cancer (MMBC) and its association with treatment pattern and disease outcomes.MethodsMMBC patients with ER, PR, HER2, and Ki67 results for each tumor focus were retrospectively analyzed using Kappa test and categorized into the homogeneous group (Homo group) and the heterogeneous group (Hetero group). Chi-square tests were performed to compare the clinical features and treatment options between the groups. Disease-free survival (DFS) and overall survival (OS) rates were estimated from Kaplan–Meier curves and compared between two groups.ResultsA total of 387 patients were included, and 93 (24.0%) were classified into the Hetero group. Adjuvant endocrine therapy was more frequently assigned for patients in the Hetero group than in the Homo group (84.9% vs. 71.7%, p = 0.046). There was no difference in terms of adjuvant anti-HER2 therapy (28.3% vs. 19.6%, p = 0.196) and chemotherapy (69.9% vs. 69.8%, p = 0.987) usage between the two groups. At a median follow-up of 36 months, DFS rates were 81.2% for the Hetero group and 96.5% for the Homo group (p = 0.041; adjusted HR, 2.95; 95% CI, 1.04–8.37). The estimated 3-year OS rates for the groups were 95.8% and 99.5%, respectively (p = 0.059; adjusted HR, 5.36; 95% CI, 0.97–29.69).ConclusionHeterogeneity of ER, PR, HER2, or Ki67 was present in 24.0% patients with MMBC. Biomarkers heterogeneity influenced adjuvant endocrine therapy usage and was associated with worse disease outcomes, indicating further clinical evaluation.https://www.frontiersin.org/articles/10.3389/fonc.2022.833093/fullbiomarkersbreast neoplasmsintertumoral heterogeneitymultifocalmulticentricprognosis |
| spellingShingle | Shuai Li Jiayi Wu Ou Huang Jianrong He Weiguo Chen Yafen Li Xiaosong Chen Kunwei Shen Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer Frontiers in Oncology biomarkers breast neoplasms intertumoral heterogeneity multifocal multicentric prognosis |
| title | Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer |
| title_full | Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer |
| title_fullStr | Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer |
| title_full_unstemmed | Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer |
| title_short | Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer |
| title_sort | association of molecular biomarker heterogeneity with treatment pattern and disease outcomes in multifocal or multicentric breast cancer |
| topic | biomarkers breast neoplasms intertumoral heterogeneity multifocal multicentric prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.833093/full |
| work_keys_str_mv | AT shuaili associationofmolecularbiomarkerheterogeneitywithtreatmentpatternanddiseaseoutcomesinmultifocalormulticentricbreastcancer AT jiayiwu associationofmolecularbiomarkerheterogeneitywithtreatmentpatternanddiseaseoutcomesinmultifocalormulticentricbreastcancer AT ouhuang associationofmolecularbiomarkerheterogeneitywithtreatmentpatternanddiseaseoutcomesinmultifocalormulticentricbreastcancer AT jianronghe associationofmolecularbiomarkerheterogeneitywithtreatmentpatternanddiseaseoutcomesinmultifocalormulticentricbreastcancer AT weiguochen associationofmolecularbiomarkerheterogeneitywithtreatmentpatternanddiseaseoutcomesinmultifocalormulticentricbreastcancer AT yafenli associationofmolecularbiomarkerheterogeneitywithtreatmentpatternanddiseaseoutcomesinmultifocalormulticentricbreastcancer AT xiaosongchen associationofmolecularbiomarkerheterogeneitywithtreatmentpatternanddiseaseoutcomesinmultifocalormulticentricbreastcancer AT kunweishen associationofmolecularbiomarkerheterogeneitywithtreatmentpatternanddiseaseoutcomesinmultifocalormulticentricbreastcancer |